The COVID-19 variant BA.3.2, nicknamed "Cicada," has been detected in at least 23 countries and half the states in the U.S.
Phase 4 COMPARE trial data show Nuvaxovid was associated with lower reactogenicity and fewer daily activity disruptions than mNEXSPIKE.
Get the latest news stories and videos on the Coronavirus with trackers on vaccines, hospitalizations, and deaths.
BrainCheck Inc., a cognitive workflow platform, today highlighted the publication of a peer-reviewed longitudinal study conducted at UTHealth Houston that used BrainCheck to track cognitive outcomes ...
Older adults and immunocompromised individuals in England face a disproportionately higher burden of severe influenza outcomes and hospitalizations.